Vol. 6 No. 5 (2026): May
Reimbursement Reviews

Risperidone Long-Acting Injection (Okedi)

decorative image of the issue cover

Published May 13, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses risperidone long-acting injection (Okedi), 75 mg or 100 mg, powder for extended-release suspension, intramuscular injection.
  • Indication: The treatment of schizophrenia in adults.